Who is sponsoring NCT05451368?

NCT05451368 is sponsored by Shenyang Northern Hospital.

What drugs are being tested in NCT05451368?

Interventions in NCT05451368: Coronary artery calcification lesions.

What condition does NCT05451368 study?

NCT05451368 studies Coronary Artery Calcification, Restenosis, Neointima, Neoatherosclerosis.

Is NCT05451368 still recruiting?

NCT05451368 is currently status unknown. Last updated 19 July 2022.

Last reviewed 2022-07-19 · How we verify

NCT05451368

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neointimal Features in Patients With Restenosis of Calcified Lesions

Status unknown Last updated 19 July 2022

What this trial tests

trial testing Coronary artery calcification lesions in Coronary Artery Calcification in 120 participants. Status unknown.

Timeline

17 March 2022

Primary endpoint
28 February 2023

31 March 2023

Quick facts

Lead sponsor	Shenyang Northern Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	120
Start date	17 March 2022
Primary completion	28 February 2023
Estimated completion	31 March 2023
Sites	1 location across China

Drugs / interventions tested

Coronary artery calcification lesions

Conditions studied

Coronary Artery Calcification — all drugs for Coronary Artery Calcification →
Restenosis — all drugs for Restenosis →
Neointima — all drugs for Neointima →
Neoatherosclerosis — all drugs for Neoatherosclerosis →

Sponsor

Shenyang Northern Hospital

Who can join

18 and older, any sex, with Coronary Artery Calcification or Restenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Previous studies have suggested that restenosis (RS) after stenting is mainly due to smooth muscle cell proliferation and migration, but recent evidence suggests that in-stent restenosis（ISR） is associated with a number of factors. Coronary artery calcification is an independent predictor of ischaemia-mediated revascularisation 1 year after percutaneous coronary intervention (PCI) following RS.The characteristics of new neointima in patients with in-stent restenosis of calcified lesions are important issues to explore

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Calcification

Currently open trials in the same condition.

NCT07340294 — ClinicAL outComes of IntraVascular Lithotripsy Combined With Conventional Lesion Preparation in Patients With Moderate t · NA · active not recruiting
NCT07400406 — A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance for the Detection of Calcified Coronary Arteries · recruiting
NCT06181240 — Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE) · NA · active not recruiting
NCT05845424 — High-intensity Statin and Ezetimibe Therapy for Asymptomatic Patients With Positive Coronary Calcium · Phase 4 · recruiting
NCT05346068 — The Value of IVL Compared To OPN Non-Compliant Balloons for Treatment of RefractorY Coronary Lesions (VICTORY) Trial · NA · recruiting

Other Shenyang Northern Hospital trials

Trials by the same sponsor.

NCT07445360 — Circumferential Pulmonary Venous Isolation Combined With Bachmann Bundle Modification Versus Circumferential Pulmonary V · NA · not yet recruiting
NCT07374718 — Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate- · NA · not yet recruiting
NCT07351643 — CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HF · Phase 4 · not yet recruiting
NCT07362966 — Effect of Colchicine on Progression of Coronary Atherosclerosis in Patients With TET2-CHIP Variant · Phase 4 · not yet recruiting
NCT07383155 — Bivalirudin Versus Heparin During PCI in High Bleeding Risk Patients With Acute Coronary Syndromes · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05451368 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenyang Northern Hospital
Last refreshed: 19 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05451368.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing